Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I SAD Study of AZD4041 in Healthy Volunteers
NCT04076540Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2019
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in nicotine dependence comparing AZD4041 with Placebo (2 arms). Primary endpoints: Number of Adverse Events at 6 weeks, Number of Participants With Treatment Emergent Adverse Events at 6 weeks and 5 more. Started Oct 2019; status: completed.
02
Drugs
AZD4041
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT04076540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04076540.